PDF(Pubmed)
Abstract：
Diabetic foot ulcers (DFUs) pose a critical medical challenge, significantly im-pairing the quality of life of patients. Adipose-derived stem cells (ADSCs) have been identified as a promising therapeutic approach for improving wound healing in DFUs. Despite extensive exploration of the mechanical aspects of ADSC therapy against DFU, its clinical applications remain elusive. In this review, we aimed to bridge this gap by evaluating the use and advancements of ADSCs in the clinical management of DFUs. The review begins with a discussion of the classification and clinical management of diabetic foot conditions. It then discusses the current landscape of clinical trials, focusing on their geographic distribution, reported efficacy, safety profiles, treatment timing, administration techniques, and dosing considerations. Finally, the review discusses the preclinical strategies to enhance ADSC efficacy. This review shows that many trials exhibit biases in study design, unclear inclusion criteria, and intervention protocols. In conclusion, this review underscores the potential of ADSCs in DFU treatment and emphasizes the critical need for further research and refinement of therapeutic approaches, with a focus on improving the quality of future clinical trials to enhance treatment outcomes and advance the field of diabetic wound care.
摘要：
糖尿病足溃疡（DFU）构成了严峻的医学挑战，显着提高患者的生活质量。脂肪来源的干细胞（ADSC）已被确定为改善DFU伤口愈合的有希望的治疗方法。尽管对ADSC治疗DFU的机械方面进行了广泛的探索，其临床应用仍然难以捉摸。在这次审查中,我们旨在通过评估ADSCs在DFU临床管理中的使用和进展来弥补这一差距.该综述首先讨论了糖尿病足病的分类和临床管理。然后讨论临床试验的现状，关注它们的地理分布，报告的疗效，安全概况,治疗时机,管理技术，和剂量考虑。最后,这篇综述讨论了提高ADSC疗效的临床前策略.这篇综述表明，许多试验在研究设计中表现出偏见，纳入标准不明确，和干预协议。总之,这篇综述强调了ADSCs在DFU治疗中的潜力，并强调了进一步研究和完善治疗方法的关键需求，重点是提高未来临床试验的质量，以提高治疗效果并推进糖尿病伤口护理领域。
